UNSPSC 85813611: Introduction of oxazolidinones into lymphatics, percutaneous approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of oxazolidinones into lymphatics, percutaneous approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0W328

UNSPSC 85813611 Introduction of oxazolidinones into lymphatics, percutaneous approach is a Commodity code that does not align with recent state and local procurement activity in the dataset. The code nominally describes a pharmaceutical or clinical procedure involving oxazolidinone compounds, but the recent opportunities tagged under this code span virtual urgent care services, medical director functions for EMS systems, occupational health screening, cancer registry and retinal screening services, EMT staffing, employee health clinics, wellness programs, opioid use disorder treatment, behavioral health services, and various diagnostic and therapeutic specialties—none of which involve the introduction of oxazolidinones into lymphatics. State and local buyers are not sourcing this specific clinical procedure through competitive procurement; the mismatch between the code's technical scope and the actual health services being purchased suggests either systematic miscoding or the code's inapplicability to the state and local market.

The opportunities in the dataset reveal a broad, fragmented health services procurement landscape spanning state health departments, county health systems, municipal fire departments, school districts, and regional health authorities. Issuing bodies include the Nevada Health Authority (PACE programs, rural value-based care networks), the Colorado Department of Human Services (nursing home placement beds), multiple counties in California, Georgia, Kansas, and Florida (occupational health, wellness, emergency services staffing), and specialized transit and behavioral health entities. No recent opportunities directly involve oxazolidinone pharmaceutical administration, and no vendor should pursue this code based on current market signals. Procurement activity under the tagged code reflects either a data-quality issue or a fundamental misclassification that renders the code unreliable for business development targeting.